Wedbush analyst Yun Zhong initiated coverage of Rocket Pharmaceuticals (RCKT) with an Outperform rating and $32 price target
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Rocket Pharmaceuticals initiated with a Buy at Jefferies
- Rocket Pharmaceuticals price target lowered to $40 from $44 at Leerink
- Rocket Pharmaceuticals 13.2M share Spot Secondary priced at $12.50
- Closing Bell Movers: Dave & Busters down 11% after Q3 miss
- Rocket Pharmaceuticals announces $150M common stock offering